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Cardiac sympathetic dysfunction was investigated using 123I-
metaiodobenzylguanidine (MIBG) myocardial scintigraphy
in 20 patients with drug induced parkinsonism (DIP). The
mean heart to mediastinum ratio was significantly greater in
patients with DIP than in those with Parkinson’s disease
(mean (SD): 2.07 (0.39) v 1.28 (0.15), p,0.001). MIBG
uptake was not different between the DIP patients and
controls. Two DIP patients whose MIBG uptake was
significantly reduced showed persistent parkinsonism and
responded dramatically to levodopa.
D
rug induced parkinsonism (DIP) comprises 10–30% of
all cases of parkinsonism.1–3 The clinical manifestations
of DIP resemble those of Parkinson’s disease, including
high frequency of tremor and asymmetrical signs.4–8 After
discontinuation of the offending drug, most patients with
DIP are free of parkinsonism within a few weeks.9 However,
DIP is not always reversible. It has been reported that
Parkinson’s disease can develop after apparent recovery from
DIP, and that it can persist and eventually worsen after
discontinuation of the offending drug.5 9 10
There is little published information about functional
imaging in patients with DIP. Using F-dopa PET, only Burn
and Brooks9 systemically reported the integrity of nigros-
triatal projections in patients with DIP, showing that 31% of
cases had underlying nigrostriatal dysfunction. 123I-metaio-
dobenzylguanidine (MIBG) is a noradrenaline (norepinephr-
ine) analogue that is taken up and stored in the sympathetic
nerve endings.11 It was shown recently that cardiac MIBG
uptake is significantly reduced in patients with Parkinson’s
disease.12 In the present study, we investigated cardiac
sympathetic dysfunction in patients with DIP, using MIBG
myocardial scintigraphy.
METHODS
We prospectively enrolled 20 patients with DIP, 32 with
Parkinson’s disease, and 20 healthy controls. DIP was defined
by the following criteria:
N the presence of least two of four cardinal signs (tremor,
rigidity, bradykinesia, and impaired postural reflexes);
N the absence of a personal history of extrapyramidal
disorders before treatment with the offending drug;
N onset of symptoms in the course of treatment with the
offending drug.
Parkinson’s disease was diagnosed according to United
Kingdom Parkinson’s disease Society Brain Bank clinical
diagnosis criteria.13 All patients with DIP were followed up
closely for nine months after withdrawal of the offending
drug. The clinical stages of parkinsonism were assessed at the
beginning of evaluation and nine months after withdrawal of
the offending drug according to the classification of Hoehn
and Yahr.14 None of the patients had a history of neuropathy
or previous relevant cardiac disease, and routine chest
radiography and electrocardiography showed no abnormal-
ities. As a control group, age matched subjects with no
history of neurological or heart disease were enrolled.
The 123I-MIBG (111 mBq) was injected intravenously into
each subject. Three hours later, the image of cardiac uptake
was taken using dual head gamma camera system
(MultiSPECT III, Siemens Medical Systems, Malvern,
Pennsylvania, USA). The region of interest was placed on
the whole heart and mediastinum of the frontal image. The
ratio of 123I-MIBG uptake in regions of interest of the heart to
that in mediastinum (H/M ratio) was calculated. Informed
consent was obtained from all subjects.
The Mann–Whitney U test was used for examining the
intentional difference between two groups using commercially
available software package (SPSS, version 10.0). Probability
(p) values less than 0.05 were considered significant.
RESULTS
There was no difference in age among the patients with DIP
(mean (SD), 65.8 (7.9) years), patients with Parkinson’s
disease (64.6 (11.4) years), and the controls (63.7 (10.1)
years). The female to male ratio tended be higher in patients
with DIP than in the controls (75% v 45%, p = 0.053). The
mean duration of parkinsonism in patients with Parkinson’s
disease and DIP was 3.7 (2.6) years and 8 (1) months,
respectively. The details of DIP patients and their offending
drugs are summarised in table 1.
The mean H/M ratio was significantly greater in patients
with DIP than in those with Parkinson’s disease (2.07 (0.39)
v 1.28 (0.15), p,0.001). However, the mean H/M ratio for the
DIP group was not significantly different from that in the
control group (2.06 (0.33)). Figure 1 shows a scatterplot of
the individual cardiac MIBG uptakes in 20 patients with DIP,
compared with the Parkinson’s disease patients and the
controls. Eighteen of 20 patients with DIP had an H/M ratio
that lay within 2 SD of the normal mean, but two lay more
than 2 SD below the normal mean and fell within the range
of the Parkinson patients.
Eighteen patients with DIP whose MIBG uptake lay within
the normal range showed dramatic improvement or complete
resolutionofparkinsonismonclinical followupafterwithdrawal
of the offending drug, whereas two DIP patients (numbers 7
and 16) whose MIBG uptake was significantly reduced had
persistent parkinsonism. Both of these patients responded well
to treatment with levodopa (54% and 76% improvement on
motor UPDRS, respectively). There were no clinical character-
istics that distinguished those patients who subsequently
improved from their parkinsonism from those who did not.
Abbreviations: DIP, drug induced parkinsonism; H/M ratio, heart to
mediastinum ratio; MIBG, 123I-metaiodobenzylguanidine; UPDRS,
Unified Parkinson’s Disease Rating Scale
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DISCUSSION
Neuroleptics, calcium channel blocker, and dopamine deplet-
ing agents all have effects on dopaminergic receptors that
may result in DIP. There may be several possible outcomes15:
full and long lasting recovery of DIP with no subsequent
development of Parkinson’s disease (that is, DIP is unrelated
to Parkinson’s disease); persistence and eventual worsening
of parkinsonism after discontinuation of the offending drug
(DIP unmasks Parkinson’s disease); full remission of DIP
after withdrawal of the offending drug with subsequent
reappearance of parkinsonism (DIP antedates Parkinson’s
disease).
It is difficult to identify preclinical Parkinson’s disease in
patients with DIP because the reversibility of parkinsonian
features does not rule out preclinical Parkinson’s disease, nor
does a clinically rapid resolution of parkinsonism preclude
the later development of Parkinson’s disease. Moreover, a
patient with DIP that is unrelated to Parkinson’s disease
cannot be distinguished from a DIP patient who has
subclinical Parkinson’s disease.15 However, as the prognosis
and treatment strategies for DIP and Parkinson’s disease are
different, it is important to be able to recognise subclinical
Parkinson’s disease.
In an F-dopa PET study, Burn and Brooks identified nigral
dysfunction in DIP patients.9 They suggested that subclinical
nigral pathology was a relatively common occurrence in DIP
patients, and that affected individuals had continued or
worsening parkinsonism, in contrast to those with normal
putamenal tracer uptake, who showed subsequent improve-
ment of parkinsonism. In our study, most of the patients
with DIP (90%) had cardiac MIBG uptake within the normal
range, suggesting that they did not have the sympathetic
dysfunction seen in Parkinson’s disease, and that their DIP
may be unrelated to Parkinson’s disease. However, two
patients with DIP (10% of the DIP group) showed markedly
low cardiac MIBG uptake, falling into the range of
Parkinson’s disease patients. As in the study by Burns and
Brooks,9 the two patients with low cardiac MIBG uptake had
persistent parkinsonism after the offending drug was with-
drawn, and both patients responded dramatically to levo-
dopa. Thus it is speculated that in these patients the
offending drugs may have aggravated the potential dopami-
nergic defect and thus unmasked the clinical manifestation
of Parkinson’s disease.
Various drugs have been reported to influence cardiac
MIBG uptake.11 Haloperidol decreases MIBG uptake at very
highly concentration, however—which is far above that
achieved therapeutically.16 Cilnidipine, third generation dihy-
dropyridine based calcium antagonist, is reported to enhance
cardiac MIBG uptake and this would lead to falsely raised
values; however, this effect is likely to be minimal because
the increase in the H/M ratio after cilnidipine treatment is
very slight (,0.1).17 Chlorpromazine and perphenazine might
be expected to interfere with cardiac MIBG uptake11;
however, there was no direct evidence of this. Finally, there
are no reports of drug interactions between levosulpiride,
metoclopramide, or risperidone and MIBG. Thus we believe
that in present study the influence of the offending drugs on
the MIBG uptake was likely to have been trivial. Because the
number of offending drugs was small, however, we were
unable to show in this study whether DIP patients without
preclinical Parkinson’s disease all have a normal MIBG
uptake or not.
Compared with F-dopa PET, 123I-MIBG myocardial scinti-
graphy is more widely available, requires less sophisticated
equipment and analytic procedures, and is cheaper. Our
study suggests that cardiac MIBG uptake is in the normal
range in a majority of patients with DIP, suggesting that in
these patients the condition is unrelated to Parkinson’s
disease. However, cardiac MIBG uptake can be abnormal in
some patients with DIP and in these cases the disorder is
clinically similar to Parkinson’s disease.
Table1 The demographic features in patients with dug induced parkinsonism and their
offending drugs
Patient Age/sex Offending drug (duration, month) Initial H&Y Follow up H&Y
1 65/F Levosulpiride (6) 2.5 0
2 69/F Levosulpiride (10) 2 0
3 71/F Levosulpiride (5) 2.5 0
4 51/M Levosulpiride (18) 2 0
5 70/F Levosulpiride (20) 3 0
6 67/F Levosulpiride (46) 2.5 0
7 72/M Levosulpiride (4) 2.5 2.5
8 76/F Levosulpiride (6) 3 1
9 67/F Levosulpiride (2) 2 0
10 66/F Levosulpiride (10) 3 0
11 64/F Metoclopramide (5) 2.5 0
12 68/M Perphenazine (120) 3 1
13 73/M Perphenazine (84) 2.5 0
14 60/F Perphenazine (26) 2.5 0
15 41/F Risperidone (5) 5 1
16 68/F Risperidone (2) 2.5 2
17 65/M Risperidone (5) 3 0
18 64/F Chlorpromazine (20) 4 1
19 72/F Haloperidol (5) 2.5 0
20 66/F Cilnidipine (12) 2.5 0
H&Y, Hoehn and Yahr stage.
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Figure 1 Scatter diagram of individual heart to mediastinum ratio (H/
M ratio) of 123I-MIBG uptake in patients with drug induced parkinsonism
(DIP), compared with patients with Parkinson’s disease (PD) and the
controls. Horizontal lines indicate the mean values.
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A recent study suggests that low MIBG uptake does not
necessarily indicate Parkinson’s disease.18 Thus further
studies using fluorodopa PET or dopamine transporter
imaging need to be done to identify whether DIP patients
with reduced cardiac MIBG uptake may have nigral
dopaminergic degeneration.
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